The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy and safety of docetaxel (D) vs androgen-receptor signaling inhibitors (ARSi) as second-line therapy (Rx) after progression on alternative ARSi as first-line Rx for patients who are elderly (≥75 years old) with metastatic castration-resistant prostate cancer (mCRPC) in a multicenter international database: A SPARTACUSS–Meet-URO 26 study.
 
Vincenzo Gennusa
No Relationships to Disclose
 
Calogero Saieva
No Relationships to Disclose
 
Richard M. Lee-Ying
Honoraria - Amgen; Janssen
Consulting or Advisory Role - Amgen; AstraZeneca Canada; Bayer; Bristol-Myers Squib; Celgene; Eisai; Ipsen; Ipsen; Janssen; Merck; Pfizer; Sanofi
Speakers' Bureau - Amgen; Celgene; Janssen
Research Funding - Sanofi
 
Pier Vitale Nuzzo
No Relationships to Disclose
 
Gian Paolo Spinelli
No Relationships to Disclose
 
Elisa Zanardi
Honoraria - Bristol-Myers Squibb/Pfizer
Consulting or Advisory Role - Astellas Pharma; Ipsen; Janssen Oncology
Speakers' Bureau - Bristol-Myers Squibb/Pfizer
Travel, Accommodations, Expenses - Janssen Oncology
 
Giuseppe Fotia
No Relationships to Disclose
 
Sabrina Rossetti
No Relationships to Disclose
 
Loana Bueno Valenca
No Relationships to Disclose
 
Anna Patrikidou
No Relationships to Disclose
 
Livia Andrade
Consulting or Advisory Role - Astellas Pharma; Janssen-Cilag; Zodiac Pharma
Speakers' Bureau - Daiichi Sankyo/Astra Zeneca; Janssen-Cilag; Merck Sharp Dohme; Zodiac Pharma
Research Funding - Bayer; Janssen-Cilag; Regeneron; Roche/Genentech
Travel, Accommodations, Expenses - Janssen Oncology
 
Ricardo Pereira Mestre
No Relationships to Disclose
 
Giuseppe Fornarini
No Relationships to Disclose
 
Giuseppe Procopio
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb (BMS); Eisai; Ipsen; Janssen; Merck Sharp & Dohme; MSD Oncology; Novartis; Pfizer
Research Funding - Astellas Pharma; Ipsen; Janssen Oncology
 
Daniele Santini
No Relationships to Disclose
 
Christopher Sweeney
Stock and Other Ownership Interests - Leuchemix
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Genentech/Roche; Janssen Biotech; Lilly; Pfizer; POINT Biopharma; Sanofi
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Dendreon; Janssen Biotech (Inst); Pfizer (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Leuchemix, Parthenolide, Dimethylaminoparthenolide. Exelixis: Abiraterone plus cabozantinib combination
 
Daniel Yick Chin Heng
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Eisai; Ipsen; Janssen; Merck; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Exelixis (Inst); Ipsen (Inst); Novartis (Inst); Pfizer (Inst)
 
Ugo De Giorgi
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Dompé Farmaceutici; Eisai; Ipsen; Janssen; Merck KGaA; MSD; Novartis; Pfizer; PharmaMar
Research Funding - AstraZeneca (Inst); Roche (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Ipsen; Pfizer
 
Antonio Russo
No Relationships to Disclose
 
Edoardo Francini
No Relationships to Disclose